FDA Recalls Orphenadrine Citrate Tablets Due to Potential Label Mixup
Aidapak Services, LLC is recalling Orphenadrine Citrate ER tablets because they may be mislabeled as Omega-3 Fatty Acid capsules.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a labeling error (label mixup) without reported injuries or illnesses, fitting the criteria for moderate severity.
Plain-English summary
Aidapak Services, LLC is recalling Orphenadrine Citrate ER Tablets, 100 mg, NDC 43386048024. The recall is due to a labeling error where the product may be mislabeled as Omega-3 Fatty Acid Capsules, 1000 mg, NDC 40985022921.
The affected product has the pedigree W002962 and an expiration date of 6/11/2014. The repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Consumers should check their medication for the specific NDC and pedigree listed above. If the product matches the description, they should stop using it and contact their healthcare provider or pharmacist for guidance.
The recalled product
- Product
- ORPHENADRINE CITRATE ER Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 43386048024
- Manufacturer
- Aidapak Services, LLC
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 100
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- ORPHENADRINE CITRATE ER
- Tablet
- 100 mg has the folowing code Pedigree: W002962
- EXP: 6/11/2014.
Distribution
Part of a larger recall action
This product is one of 273 recalled by Aidapak Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 273 products in this recall →Related recalls
Same manufacturer · Aidapak Services, LLC
See all →- ModerateAidapak Recalls Sennosides Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29
- ModerateLevothyroxine Sodium Tablets Recalled for Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Mislabeled Pantoprazole Sodium DR Tablets
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Nifedipine ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateSimvastatin Tablets Recalled for Potential Labeling Error
FDA (Drugs) · 2014-01-29
Same hazard · mis labeling
See all →- SevereImperio Distribution Recalls Beef Jerky Produced Without Federal Inspection
USDA FSIS · 2026-10-24
- HighJ K Patisserie Chocolate Chip Cookies Recalled for Undeclared Soy
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- LowMindray ePM Series Patient Monitor Manuals Recalled for Alarm Clarification
FDA (Devices) · 2026-10-14
Similar recalls
- ModerateFDA Recalls Levothyroxine Sodium Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Exemestane Tablets Due to Potential Labeling Error
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Modafinil Tablets Due to Potential Labeling Mixup
FDA (Drugs) · 2014-01-29
- ModerateOmega-3 Acid Ethyl Esters Capsules Recalled for Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Aspirin Chew Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29
- ModerateAidapak Recalls Niacin ER Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-29